

# Cihan Ay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8429729/publications.pdf>

Version: 2024-02-01

274  
papers

12,755  
citations

23567  
58  
h-index

31849  
101  
g-index

280  
all docs

280  
docs citations

280  
times ranked

11698  
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet activation and aggregation in different centrifugal-flow left ventricular assist devices. Platelets, 2022, 33, 249-256.	2.3	6
2	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. Thrombosis and Haemostasis, 2022, 122, 353-362.	3.4	7
3	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Thrombosis and Haemostasis, 2022, 122, 633-645.	3.4	7
4	Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. Thrombosis and Haemostasis, 2022, 122, 818-829.	3.4	23
5	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Thrombosis and Haemostasis, 2022, 122, 646-656.	3.4	25
6	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. European Heart Journal, 2022, 43, 183-189.	2.2	83
7	Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Advances, 2022, 6, 946-958.	5.2	8
8	Extended anticoagulation treatment for cancer-associated thrombosisâ€”Rates of recurrence and bleeding beyond 6 months: A systematic review. Journal of Thrombosis and Haemostasis, 2022, 20, 619-634.	3.8	22
9	Lupus anticoagulant test persistence over time and its associations with future thrombotic events. Blood Advances, 2022, , .	5.2	1
10	Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach. Thrombosis and Haemostasis, 2022, 0, .	3.4	1
11	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. Journal of Hepatology, 2022, 76, 1090-1099.	3.7	26
12	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. Viruses, 2022, 14, 178.	3.3	18
13	Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need. Thrombosis Update, 2022, 6, 100098.	0.9	2
14	Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors. Thrombosis and Haemostasis, 2022, 122, 1594-1602.	3.4	8
15	Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life. Respiration, 2022, 101, 593-601.	2.6	105
16	ABO blood group type and risk of venous thromboembolism in patients with cancer. Blood Advances, 2022, 6, 6274-6281.	5.2	17
17	Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	35
18	The role of platelets in antiviral immunity. Obstetrics, Gynecology and Reproduction, 2022, 16, 204-212.	0.5	2

#	ARTICLE	IF	CITATIONS
19	Unanswered questions in cancer-associated thrombosis. British Journal of Haematology, 2022, 198, 812-825.	2.5	11
20	Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps. Best Practice and Research in Clinical Haematology, 2022, 35, 101347.	1.7	3
21	Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies. Thrombosis Research, 2022, 213, S58-S65.	1.7	12
22	Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII. Journal of Thrombosis and Haemostasis, 2022, 20, 2306-2312.	3.8	6
23	The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. Blood Advances, 2022, 6, 5467-5476.	5.2	6
24	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, The, 2022, 23, e334-e347.	10.7	138
25	First application of focused low-energy extracorporeal shockwave therapy in a patient with severe hemophilia A and plantar fasciitis. Wiener Klinische Wochenschrift, 2021, 133, 245-246.	1.9	2
26	Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals. Rheumatology, 2021, 60, 1687-1699.	1.9	15
27	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood, 2021, 137, 1669-1678.	1.4	123
28	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 297-303.	3.8	27
29	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Annals of Oncology, 2021, 32, 171-182.	1.2	42
30	Venous thromboembolism in cancer patients: a population-based cohort study. Blood, 2021, 137, 1959-1969.	1.4	277
31	Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. Blood Advances, 2021, 5, 487-495.	5.2	36
32	Bleeding Risk Assessment in Patients with Venous Thromboembolism. Hamostaseologie, 2021, 41, 267-274.	1.9	7
33	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974.	5.2	431
34	Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia – A case-based review of clinical management. Thrombosis Research, 2021, 199, 38-42.	1.7	6
35	Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer – a nationwide analysis. European Heart Journal, 2021, 42, 2299-2307.	2.2	62
36	Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis. Blood, 2021, 137, 1406-1415.	1.4	21

#	ARTICLE	IF	CITATIONS
37	Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation. <i>Cancers</i> , 2021, 13, 1487.	3.7	17
38	Pain management in hemophilia: expert recommendations. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1042-1056.	1.9	15
39	Fibrinolysis and bleeding of unknown cause. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12511.	2.3	4
40	Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. <i>Hamostaseologie</i> , 2021, 41, 184-189.	1.9	189
41	Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability. <i>Cancers</i> , 2021, 13, 2260.	3.7	16
42	Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2021, 88, 35-42.	2.2	10
43	Growth differentiation factor-15 predicts major cardiac adverse events and all-cause mortality in patients with atrial fibrillation. , 2021, 41, .		0
44	Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. <i>Scientific Reports</i> , 2021, 11, 12967.	3.3	7
45	Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1819-1822.	3.8	91
46	Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm. <i>Hamostaseologie</i> , 2021, 41, .	1.9	0
47	Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia. <i>Hamostaseologie</i> , 2021, 41, .	1.9	0
48	Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency. <i>Hamostaseologie</i> , 2021, 41, .	1.9	0
49	Peri-interventional Triple Therapy With Dabigatran Improves Vasomotion and Promotes Endothelialization in Porcine Coronary Stenting Model. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 690476.	2.4	1
50	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021, 05, e376-e386.	1.4	18
51	New Inhibitors in the Ageing Population: A retrospective, observational, cohort study of new inhibitors in older people with haemophilia. <i>Thrombosis and Haemostasis</i> , 2021, , .	3.4	0
52	Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2984-2996.	3.8	10
53	Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2837-2847.	2.4	17
54	Risk assessment models of cancer-associated thrombosis - Potentials and perspectives. <i>Thrombosis Update</i> , 2021, 5, 100075.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. Blood Advances, 2021, 5, 391-398.	5.2	18
56	Clinical characteristics and 3-month outcomes in cancer patients with incidental <i>versus</i> clinically suspected and confirmed pulmonary embolism. European Respiratory Journal, 2021, 58, 2002723.	6.7	9
57	Risk assessment for recurrent venous thromboembolism in patients with cancer. Thrombosis Update, 2021, 5, 100080.	0.9	5
58	Thrombomodulin in patients with mild to moderate bleeding tendency. Haemophilia, 2021, 27, 1028-1036.	2.1	8
59	Circulatory microRNAs as potential biomarkers for major adverse cardiac events in patients with atrial fibrillation. European Heart Journal, 2021, 42, .	2.2	1
60	Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thrombosis Research, 2021, 207, 126-130.	1.7	15
61	The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vectorâ€based COVIDâ€19 vaccination: Where there is much light, the shadow is deep. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12609.	2.3	1
62	Vaccine-induced immune thrombotic thrombocytopenia: definition, risks with different vaccines, and regulatory responses. Obstetrics, Gynecology and Reproduction, 2021, 15, 562-575.	0.5	1
63	Risk Factors in Cancer Patients. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 465-475.	0.6	2
64	Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer. Blood, 2021, 138, 2119-2119.	1.4	1
65	Renal Function and Risk of Arterial Thrombotic Events in Patients Positive for Lupus Anticoagulant. Blood, 2021, 138, 290-290.	1.4	0
66	Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. Haematologica, 2020, 105, 218-225.	3.5	117
67	Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Translational Research, 2020, 215, 41-56.	5.0	7
68	Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. Thrombosis Research, 2020, 187, 9-17.	1.7	21
69	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. European Journal of Internal Medicine, 2020, 82, 48-55.	2.2	5
70	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3Âmonths. Thrombosis Research, 2020, 196, 297-304.	1.7	5
71	Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary intervention. Thrombosis Research, 2020, 196, 31-37.	1.7	6
72	Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future. Hamostaseologie, 2020, 40, 270-279.	1.9	12

#	ARTICLE	IF	CITATIONS
73	Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. <i>Thrombosis Research</i> , 2020, 191, S3-S11.	1.7	26
74	Longitudinal analysis of extracellular vesicle-associated tissue factor activity in cancer patients. <i>Thrombosis Research</i> , 2020, 195, 215-218.	1.7	4
75	Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause. <i>Blood Advances</i> , 2020, 4, 5157-5164.	5.2	27
76	Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1178-1191.	2.3	366
77	Heparins as cancer therapy: in theory, they should have worked. <i>Lancet Haematology</i> , the, 2020, 7, e703-e704.	4.6	0
78	Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. <i>Annals of Hematology</i> , 2020, 99, 2763-2771.	1.8	17
79	Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. <i>Cancers</i> , 2020, 12, 2493.	3.7	14
80	Human milk triggers coagulation via tissue factor-exposing extracellular vesicles. <i>Blood Advances</i> , 2020, 4, 6274-6282.	5.2	16
81	Pulmonary embolism during the COVID-19 pandemic: Decline in diagnostic procedures and incidence at a university hospital. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 835-841.	2.3	28
82	Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer. <i>Cancers</i> , 2020, 12, 1619.	3.7	24
83	Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 550-561.	2.3	69
84	Outpatient Pulmonary Rehabilitation in Patients with Persisting Symptoms after Pulmonary Embolism. <i>Journal of Clinical Medicine</i> , 2020, 9, 1811.	2.4	19
85	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	6.7	31
86	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	3.9	21
87	How I Manage Cancer-Associated Thrombosis. <i>Hamostaseologie</i> , 2020, 40, 038-046.	1.9	7
88	Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1081-1086.	3.8	13
89	Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-dimer analysis: A prospective study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1348-1356.	3.8	34
90	The effect of resistance exercise on strength and safety outcome for people with haemophilia: A systematic review. <i>Haemophilia</i> , 2020, 26, 200-215.	2.1	23

#	ARTICLE	IF	CITATIONS
91	Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis. <i>Atherosclerosis</i> , 2020, 298, 1-6.	0.8	8
92	Altered platelet proteome in lupus anticoagulant (LA)-positive patientsâ€™ protein disulfide isomerase and NETosis as new players in LA-related thrombosis. <i>Experimental and Molecular Medicine</i> , 2020, 52, 66-78.	7.7	17
93	The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency. <i>European Journal of Internal Medicine</i> , 2020, 78, 34-40.	2.2	22
94	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. <i>ESMO Open</i> , 2020, 5, e000647.	4.5	4
95	Anticoagulation in Patients with Brain Metastases. , 2020, , 139-143.		0
96	Association of ABO Blood Group with Bleeding Severity in Patients with Bleeding of Unknown Cause. <i>Blood</i> , 2020, 136, 16-18.	1.4	0
97	Biomarkers of Haemostasis and Occurrence of Venous Thromboembolism Are Associated with Disease Progression and Poor Prognosis in Patients with Pancreatic Cancer. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
98	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778.	3.8	107
99	Increased Citrullinated Histone H3 Levels in the Early Post-Resuscitative Period Are Associated with Poor Neurologic Function in Cardiac Arrest Survivorsâ€™A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1568.	2.4	10
100	Atrial fibrillation in patients with endâ€™stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 578-588.	2.3	19
101	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
102	Establishing an online physical exercise program for people with hemophilia. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 558-566.	1.9	20
103	Thrombinâ€™generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1478-1488.	3.8	33
104	The role of ADAMTSâ€™13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 503-514.	2.3	35
105	Anticoagulation of cancer patients with nonâ€™valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1247-1252.	3.8	60
106	Association of complete blood count parameters, dâ€™dimer, and soluble Pâ€™selectin with risk of arterial thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1335-1344.	3.8	25
107	Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 334-341.	2.7	44
108	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 207-216.	2.3	20



#	ARTICLE	IF	CITATIONS
109	Atrial fibrillation and cancer – An unexplored field in cardiovascular oncology. Blood Reviews, 2019, 35, 59-67.	5.7	64
110	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. British Journal of Haematology, 2019, 186, 311-320.	2.5	82
111	Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Annals of Oncology, 2019, 30, 897-907.	1.2	80
112	Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement. Critical Care, 2019, 23, 62.	5.8	50
113	Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. International Journal of Cardiology, 2019, 282, 47-52.	1.7	5
114	How I treat cancer-associated thrombosis. ESMO Open, 2019, 4, e000610.	4.5	19
115	High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. Blood Advances, 2019, 3, 769-776.	5.2	17
116	P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer. Neuro-Oncology, 2019, 21, iii91-iii91.	1.2	0
117	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. Cancers, 2019, 11, 2020.	3.7	13
118	Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2019, 119, 340-347.	3.4	14
119	Low extracellular vesicle-associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis. Annals of Hematology, 2019, 98, 313-319.	1.8	8
120	Citrullinated Histone H3, a Biomarker for Neutrophil Extracellular Trap Formation, Predicts the Risk of Mortality in Patients with Cancer. Hamostaseologie, 2019, 39, .	1.9	2
121	Altered Protein Profiles in Platelets of Lupus Anticoagulant Positive Patients - New Players in LA-related Thrombosis?. , 2019, 39, .		0
122	Intraperitoneal Activation of Blood Coagulation via Tissue Factor Exposing Extracellular Vesicles in Patients with Liver Disease and Ascites. Hamostaseologie, 2019, 39, .	1.9	1
123	Programmed Cell Death Ligand 1 and Venous Thromboembolism in Patients with Primary Brain Tumors. , 2019, 39, .		0
124	The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
125	Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. Clinical and Experimental Medicine, 2018, 18, 325-336.	3.6	21
126	Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2018, 16, 1121-1127.	3.8	45



#	ARTICLE	IF	CITATIONS
127	Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1246-1249.	3.8	140
128	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <i>Oncologist</i> , 2018, 23, 822-839.	3.7	24
129	High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB). <i>Haemophilia</i> , 2018, 24, 405-413.	2.1	49
130	Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 980-988.	3.7	78
131	Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 508-518.	3.8	202
132	The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 253, 71-77.	1.7	24
133	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , 2018, 16, 9.	2.1	15
134	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Thrombosis Research</i> , 2018, 164, S203-S204.	1.7	1
135	The role of scientific publishing in the development of early career investigators. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 6-7.	2.3	2
136	The role of podoplanin in cancer-associated thrombosis. <i>Thrombosis Research</i> , 2018, 164, S34-S39.	1.7	42
137	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1875-1884.	3.4	38
138	Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting. <i>Cardiovascular Diabetology</i> , 2018, 17, 131.	6.8	9
139	Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. <i>Haematologica</i> , 2018, 103, 1549-1556.	3.5	95
140	Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1581-1589.	2.3	55
141	A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. <i>Lancet Haematology</i> , 2018, 5, e289-e298.	4.6	219
142	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.9	41
143	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 664-669.	2.3	47
144	Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases. <i>Blood</i> , 2018, 132, 2476-2476.	1.4	8

#	ARTICLE	IF	CITATIONS
145	AB0590â€¦A validation study of the pregnancy morbidity questionnaire(PMQ) in women with antiphospholipid antibodies and pregnancy morbidity. , 2018, , .		0
146	The Role of Neutrophil Extracellular Traps in Cancer-Associated Arterial Thrombosis. Blood, 2018, 132, 2508-2508.	1.4	0
147	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 753-770.	1.0	53
148	A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability. Clinical and Experimental Medicine, 2017, 17, 251-256.	3.6	16
149	Symptoms, signs, suspicion and setting: aÂPESI score for cancer-associated pulmonary embolism?. European Respiratory Journal, 2017, 49, 1602225.	6.7	5
150	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood, 2017, 129, 1831-1839.	1.4	164
151	Procoagulant extracellular vesicles in amniotic fluid. Translational Research, 2017, 184, 12-20.e1.	5.0	22
152	The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. Journal of Thrombosis and Haemostasis, 2017, 15, 1317-1321.	3.8	46
153	Platelets and hemophilia: A review of the literature. Thrombosis Research, 2017, 155, 131-139.	1.7	11
154	Serum creatinine and albumin predict sarcomaâ€specific survival in patients with myofibroblastic and fibroblastic sarcomas. Journal of Orthopaedic Research, 2017, 35, 2815-2824.	2.3	26
155	Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. ESMO Open, 2017, 2, e000188.	4.5	29
156	Myeloid but not epithelial tissue factor exerts protective anti-inflammatory effects in acid aspiration-induced acute lung injury. Journal of Thrombosis and Haemostasis, 2017, 15, 1625-1639.	3.8	14
157	Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. Journal of Experimental Medicine, 2017, 214, 2121-2138.	8.5	78
158	Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice. Thrombosis Research, 2017, 153, 101-107.	1.7	41
159	Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy. Thrombosis Research, 2017, 150, 65-72.	1.7	12
160	Human pancreatic tumors grown in mice release tissue factorâ€positive microvesicles that increase venous clot size. Journal of Thrombosis and Haemostasis, 2017, 15, 2208-2217.	3.8	63
161	Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of Atrial fibrillation and thromboembolism in patients on hemoDialysis (VIVALDI). Thrombosis Research, 2017, 158, 59-64.	1.7	16
162	Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein. Journal of Thrombosis and Haemostasis, 2017, 15, 1829-1833.	3.8	14

#	ARTICLE	IF	CITATIONS
163	Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2076-2079.	3.8	56
164	Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. <i>BMC Medicine</i> , 2017, 15, 54.	5.5	20
165	Cancer-associated venous thromboembolism: Burden, mechanisms, and management. <i>Thrombosis and Haemostasis</i> , 2017, 117, 219-230.	3.4	337
166	Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. <i>Thrombosis and Haemostasis</i> , 2017, 117, 90-98.	3.4	34
167	IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1379-1390.	3.4	36
168	Tissue Factor: Catch Me If You Can!. <i>Journal of Clinical Oncology</i> , 2017, 35, 1128-1130.	1.6	11
169	Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of Atrial Fibrillation and Thromboembolism in Patients on HemoDialysis (VIVALDI). <i>PLoS ONE</i> , 2017, 12, e0169400.	2.5	51
170	Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2016, 115, 615-621.	3.4	35
171	Epidemiology and risk factors for venous thromboembolism in lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 145-149.	2.4	22
172	Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 294-305.	3.8	52
173	Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 254.	1.7	18
174	Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. <i>Oncologist</i> , 2016, 21, 252-257.	3.7	63
175	OC-16 - Neutrophil extracellular traps and tissue factor-bearing microvesicles: a liaison dangereuse causing overt DIC in cancer patients?. <i>Thrombosis Research</i> , 2016, 140, S174-S175.	1.7	9
176	PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patients. <i>Thrombosis Research</i> , 2016, 140, S176.	1.7	3
177	Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial. <i>Clinical Science</i> , 2016, 130, 433-440.	4.3	21
178	Effect of combined treatment with immunoabsorption and membrane filtration on plasma coagulation—Results of a randomized controlled crossover study. <i>Journal of Clinical Apheresis</i> , 2016, 31, 29-37.	1.3	12
179	Peripheral blood microvesicles secretion is influenced by storage time, temperature, and anticoagulants. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 663-672.	1.5	76
180	Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. <i>Scientific Reports</i> , 2016, 6, 25171.	3.3	74

#	ARTICLE	IF	CITATIONS
181	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thrombosis and Haemostasis</i> , 2016, 116, 651-658.	3.4	79
182	Hypercoagulability, venous thromboembolism, and death in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2016, 115, 817-826.	3.4	58
183	Alterations of blood coagulation in controlled human malaria infection. <i>Malaria Journal</i> , 2016, 15, 15.	2.3	26
184	Elevated serum creatinine and low albumin are associated with poor outcomes in patients with liposarcoma. <i>Journal of Orthopaedic Research</i> , 2016, 34, 533-538.	2.3	25
185	Decrease in microvesicle-associated tissue factor activity in morbidly obese patients after bariatric surgery. <i>International Journal of Obesity</i> , 2016, 40, 768-772.	3.4	13
186	Association of platelet activation markers with cancer-associated venous thromboembolism. <i>Platelets</i> , 2016, 27, 80-85.	2.3	42
187	Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). <i>Clinical Cancer Research</i> , 2016, 22, 200-206.	7.0	39
188	VTE risk assessment in cancer. <i>Phlebologie</i> , 2016, 45, 140-145.	0.3	8
189	Venous thrombosis and cancer: from mouse models to clinical trials. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1372-1382.	3.8	112
190	Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. <i>Frontiers in Cardiovascular Medicine</i> , 2015, 2, 30.	2.4	30
191	Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause. <i>Annals of Hematology</i> , 2015, 94, 1301-1310.	1.8	11
192	Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. <i>Annals of Hematology</i> , 2015, 94, 1463-1471.	1.8	34
193	Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 390-397.	3.8	59
194	Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 582-589.	1.7	187
195	Hemoglobin, alkaline phosphatase, and C-reactive protein predict the outcome in patients with liposarcoma. <i>Journal of Orthopaedic Research</i> , 2015, 33, 765-770.	2.3	25
196	Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). <i>Blood</i> , 2015, 125, 3477-3483.	1.4	63
197	Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. <i>Thrombosis Research</i> , 2015, 136, 865-869.	1.7	16
198	Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS). <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 17-22.	3.8	61

#	ARTICLE	IF	CITATIONS
199	Thrombotic Events in Lupus Anticoagulant Positive Patients Prospectively Correlate with Clinical Risk Factors - the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). <i>Blood</i> , 2015, 126, 652-652.	1.4	0
200	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>PLoS ONE</i> , 2014, 9, e111440.	2.5	64
201	Oral anticoagulation with rivaroxaban during pregnancy: a case report. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1323-1324.	3.4	27
202	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 1645-1651.	1.2	63
203	Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2478-2485.	2.4	48
204	Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. <i>European Journal of Clinical Investigation</i> , 2014, 44, 319-324.	3.4	18
205	Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients. <i>Clinical and Experimental Immunology</i> , 2014, 177, 253-260.	2.6	33
206	Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2014, 111, 670-678.	3.4	88
207	Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. <i>Thrombosis Research</i> , 2014, 134, 44-49.	1.7	28
208	Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 126-132.	2.4	5
209	Outcome of Total Knee Arthroplasty in Hemophilic Arthropathy. <i>Journal of Arthroplasty</i> , 2014, 29, 749-752.	3.1	26
210	Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. <i>Thrombosis Research</i> , 2014, 134, 1093-1096.	1.7	15
211	Statins are Associated with Low Risk of Venous Thromboembolism in Patients with Cancer: A Prospective and Observational Cohort Study. <i>Thrombosis Research</i> , 2014, 134, 1008-1013.	1.7	27
212	Characterisation of inflammatory response, coagulation, and radiological findings in Katayama fever: a report of three cases at the Medical University of Vienna, Austria. <i>BMC Infectious Diseases</i> , 2014, 14, 357.	2.9	1
213	Comparison of metal on metal versus polyethyleneâ€“ceramic bearing in uncemented total hip arthroplasty in patients with haemophilic arthropathy. <i>International Orthopaedics</i> , 2014, 38, 1369-1373.	1.9	8
214	Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. <i>Translational Research</i> , 2014, 163, 145-150.	5.0	46
215	Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. <i>Thrombosis Research</i> , 2014, 133, 303-305.	1.7	28
216	Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). <i>Thrombosis Research</i> , 2014, 133, S39-S43.	1.7	63

#	ARTICLE	IF	CITATIONS
217	Comment on Ferroni et al.: "Impact of chemotherapy on venous thromboembolism.: Comment to: Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study" HAEMATOL/2012/073338 and HAEMATOL/2013/092528. Haematologica, 2014, 99, e28-e29.	3.5	0
218	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. Blood, 2014, 124, 2859-2859.	1.4	3
219	Platelets in cancer and thrombosis. Hamostaseologie, 2014, 34, 54-62.	1.9	83
220	Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. European Journal of Clinical Investigation, 2013, 43, 277-285.	3.4	59
221	Biomarkers for prediction of venous thromboembolism in cancer. Blood, 2013, 122, 2011-2018.	1.4	208
222	Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thrombosis Research, 2013, 131, 162-165.	1.7	53
223	Response to antiplatelet therapy is independent of endogenous thrombin generation potential. Thrombosis Research, 2013, 132, e24-e30.	1.7	11
224	Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis, 2013, 11, 1069-1077.	3.8	12
225	Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2013, 11, 1993-2000.	3.8	20
226	Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica, 2013, 98, 1309-1314.	3.5	65
227	The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 79-84.	3.4	19
228	Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 2012, 30, 3870-3875.	1.6	110
229	High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica, 2012, 97, 1158-1164.	3.5	269
230	Venous thromboembolism in cancer patients – Risk scores and recent randomised controlled trials. Thrombosis and Haemostasis, 2012, 108, 1042-1048.	3.4	58
231	Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thrombosis Research, 2012, 129, S6-S9.	1.7	36
232	Association of elevated soluble P-selectin levels with fetal loss in women with a history of venous thromboembolism. Thrombosis Research, 2012, 129, 725-728.	1.7	4
233	Surgical treatment of the haemophilic pseudotumour: A single centre experience. International Orthopaedics, 2012, 36, 2157-2162.	1.9	29
234	Treatment and secondary prevention of venous thrombo-embolism in cancer patients. Hamostaseologie, 2012, 32, 139-144.	1.9	5



#	ARTICLE	IF	CITATIONS
235	Risk of venous thromboembolism and primary prophylaxis in cancer. <i>Hamostaseologie</i> , 2012, 32, 132-137.	1.9	16
236	Clinical significance of circulating microparticles for venous thrombo - embolism in cancer patients. <i>Hamostaseologie</i> , 2012, 32, 127-131.	1.9	30
237	Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1363-1370.	3.8	228
238	Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. <i>European Journal of Clinical Investigation</i> , 2012, 42, 470-477.	3.4	25
239	Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. <i>Annals of Hematology</i> , 2012, 91, 109-113.	1.8	20
240	Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. <i>Journal of Vascular Surgery</i> , 2011, 54, 48S-55S.	1.1	44
241	The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. <i>Atherosclerosis</i> , 2011, 217, 135-138.	0.8	5
242	The role of fibrinogen plasma levels, the 455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 908-913.	3.4	26
243	Thrombosis risk and survival in cancer patients with elevated C-reactive protein. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 57-63.	3.8	52
244	Prediction of Venous Thromboembolism in Patients With Cancer by Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2099-2103.	1.6	196
245	Circulating procoagulant microparticles in cancer patients. <i>Annals of Hematology</i> , 2011, 90, 447-453.	1.8	65
246	Long-term survival of patients with a history of venous thromboembolism. <i>Annals of Hematology</i> , 2011, 90, 585-594.	1.8	14
247	Thrombin generation in patients with a bleeding tendency of unknown origin. <i>Annals of Hematology</i> , 2011, 90, 1099-1104.	1.8	18
248	Decreased ADAMTS13 Activity Levels in Patients with a Bleeding Tendency of Unknown Origin. <i>Blood</i> , 2011, 118, 1218-1218.	1.4	1
249	Function of platelets in apheresis platelet concentrates and in patient blood after transfusion as assessed by Impact-R. <i>Transfusion</i> , 2010, 50, 1036-1042.	1.6	5
250	Prediction of venous thromboembolism in cancer patients. <i>Blood</i> , 2010, 116, 5377-5382.	1.4	643
251	High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 114-120.	3.8	195
252	Thrombin generation in morbid obesity: significant reduction after weight loss. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 759-765.	3.8	91



#	ARTICLE	IF	CITATIONS
253	Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women. Haemophilia, 2010, 16, 111-117.	2.1	32
254	Combined effects of genetic polymorphisms of P-selectin and P-selectin glycoprotein ligand-1 on the binding of platelets to monocytes. Thrombosis Research, 2010, 125, 475-477.	1.7	5
255	Tests predictive of thrombosis in cancer. Thrombosis Research, 2010, 125, S12-S15.	1.7	26
256	Long-Term Survival of Patients with a History of Venous Thromboembolism. Blood, 2010, 116, 3168-3168.	1.4	0
257	The Metabolic SYNDROME and the RISK of Venous Thrombosis: RESULTS of AN Individual LEVEL Patient Meta-ANALYSIS. Blood, 2010, 116, 3177-3177.	1.4	0
258	High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2176-2181.	2.4	139
259	Biomarkers and Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 332-336.	2.4	143
260	D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 2009, 27, 4124-4129.	1.6	343
261	Immunthrombozytopenie. Wiener Klinische Wochenschrift Education, 2009, 4, 153-163.	0.0	0
262	The â€˜GGCCâ€™ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia, 2009, 23, 1924-1926.	7.2	68
263	Circulating procoagulant microparticles in patients with venous thromboembolism. Thrombosis Research, 2009, 123, 724-726.	1.7	49
264	Response: P-selectin ready for the â€œNews at Sixâ€• Blood, 2009, 113, 1860-1861.	1.4	0
265	The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs. Haemophilia, 2008, 14, 703-708.	2.1	50
266	High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood, 2008, 112, 2703-2708.	1.4	366
267	P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. Thrombosis and Haemostasis, 2008, 99, 899-904.	3.4	29
268	Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood, 2008, 112, 3824-3824.	1.4	2
269	Venous thromboembolism a manifestation of the metabolic syndrome. Haematologica, 2007, 92, 374-380.	3.5	137
270	The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. Thrombosis and Haemostasis, 2007, 98, 777-782.	3.4	22

#	ARTICLE	IF	CITATIONS
271	High Concentrations of Soluble P-Selectin Are Associated with Risk of Venous Thromboembolism and the P-Selectin Thr715 Variant. Clinical Chemistry, 2007, 53, 1235-1243.	3.2	110
272	Low-density lipoprotein receptor-related protein 1 polymorphism 663 C→T affects clotting factor VIII activity and increases the risk of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2007, 5, 497-502.	3.8	56
273	Successful outcome in a pregnant woman with homozygous antithrombin deficiency. Thrombosis and Haemostasis, 2007, 98, 1377-1378.	3.4	14
274	The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. Data from a case control study. Thrombosis and Haemostasis, 2007, 98, 777-82.	3.4	10